AU2009238370B2 — Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
Assigned to Allergan Inc · Expires 2011-07-21 · 15y expired
What this patent protects
C NRPorb\CC\CRN\261062_I DOC-2/12/209 ALPHA 2B OR 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATION Methods of preventing or retarding the degeneration of neurons. Also disclosed are methods for treating Alzheimer's disease or Parkinson's disease through the admi…
USPTO Abstract
C NRPorb\CC\CRN\261062_I DOC-2/12/209 ALPHA 2B OR 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATION Methods of preventing or retarding the degeneration of neurons. Also disclosed are methods for treating Alzheimer's disease or Parkinson's disease through the administration of selective alpha 2B or alpha 2B/2C receptor agonists, hereby incorporated by reference herein.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.